Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;3(5):431-7.
doi: 10.1007/s12265-010-9204-8. Epub 2010 Jul 13.

Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies

Stephen J Gardell  1 , Gregory P Roth, Daniel P Kelly
Affiliations

Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies

Stephen J Gardell et al. J Cardiovasc Transl Res. 2010 Oct.

Abstract

The flow of innovative, effective, and safe new drugs from pharmaceutical laboratories for the treatment and prevention of cardiovascular disease has slowed to a trickle. While the need for breakthrough cardiovascular disease drugs is still paramount, the incentive to develop these agents has been blunted by burgeoning clinical development costs coupled with a heightened risk of failure due to the unprecedented nature of the emerging drug targets and increasingly challenging regulatory environment. A fuller understanding of the drug targets and employing novel biomarker strategies in clinical trials should serve to mitigate the risk. In any event, these current challenges have evoked changing trends in the pharmaceutical industry, which have created an opportunity for non-profit biomedical research institutions to play a pivotal partnering role in early stage drug discovery. The obvious strengths of academic research institutions is the breadth of their scientific programs and the ability and motivation to "go deep" to identify and characterize new target pathways that unlock the specific mysteries of cardiovascular diseases--leading to a bounty of novel therapeutic targets and prescient biomarkers. However, success in the drug discovery arena within the academic environment is contingent upon assembling the requisite infrastructure, annexing the talent to interrogate and validate the drug targets, and building translational bridges with pharmaceutical organizations and patient-oriented researchers.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. J Clin Invest. 2006 Nov;116(11):2837-42 - PubMed
    1. Harv Bus Rev. 2008 May;86(5):68-70, 72-6, 128 - PubMed
    1. Nat Rev Drug Discov. 2010 Mar;9(3):203-14 - PubMed
    1. Nat Rev Drug Discov. 2010 Mar;9(3):183 - PubMed

MeSH terms

Substances

LinkOut - more resources